Comparing MyMD Pharmaceuticals (MYMD) and Its Rivals

MyMD Pharmaceuticals (NASDAQ:MYMDGet Rating) is one of 40 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its competitors? We will compare MyMD Pharmaceuticals to similar businesses based on the strength of its institutional ownership, dividends, analyst recommendations, valuation, risk, profitability and earnings.

Insider and Institutional Ownership

12.4% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 49.2% of shares of all “Diagnostic substances” companies are held by institutional investors. 11.3% of MyMD Pharmaceuticals shares are held by insiders. Comparatively, 11.2% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares MyMD Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MyMD Pharmaceuticals $1.58 million -$29.89 million -5.98
MyMD Pharmaceuticals Competitors $411.38 million $32.43 million -65.69

MyMD Pharmaceuticals’ competitors have higher revenue and earnings than MyMD Pharmaceuticals. MyMD Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations for MyMD Pharmaceuticals and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MyMD Pharmaceuticals 0 0 0 0 N/A
MyMD Pharmaceuticals Competitors 200 545 1145 18 2.51

As a group, “Diagnostic substances” companies have a potential upside of 77.25%. Given MyMD Pharmaceuticals’ competitors higher possible upside, analysts plainly believe MyMD Pharmaceuticals has less favorable growth aspects than its competitors.

Risk and Volatility

MyMD Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals’ competitors have a beta of 1.40, suggesting that their average stock price is 40% more volatile than the S&P 500.


This table compares MyMD Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MyMD Pharmaceuticals N/A -77.76% -69.92%
MyMD Pharmaceuticals Competitors -2,615.40% -73.84% -34.36%


MyMD Pharmaceuticals competitors beat MyMD Pharmaceuticals on 7 of the 10 factors compared.

About MyMD Pharmaceuticals

(Get Rating)

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with's FREE daily email newsletter.